Business
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
BOCA RATON, Fla., January 07, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference.
About this update from Sensus Healthcare, Inc.
[{"type":"text","content":"BOCA RATON, Fla., January 07, 2026--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference.","length":463,"tagName":"p"},{"type":"text","content":""With recently established coding by the Centers for Medicare & Medicaid Services validating our superficial radiotherapy for the non-invasive treatment of non-melanoma skin cancer, along with positive momentum with our Fair Deal Agreement program and an expanding international footprint, 2026 looks to be exciting and highly productive for Sensus," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "We look forward to sharing the Sensus story as the global healthcare investment community kicks off the year in San Francisco."","length":580,"tagName":"p"},{"type":"text","content":"Investors and others interested in scheduling a private meeting with Sensus Healthcare management at the Alliance Advisors IR’s 22nd Annual Investor Offsite Event during JPM Week should contact Tirth Patel at [email protected].","length":237,"tagName":"p"},{"type":"text","content":"About Sensus Healthcare","length":23,"tagName":"p"},{"type":"text","content":"Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.","length":548,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"This press release includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these statements can be identified by the use...